Urinary Incontinence, Stress
Conditions
Brief summary
The purpose of this study is to determine how effective duloxetine is in treating women who are 65 years of age or older with symptoms of stress urinary incontinence, or with a combination of stress urinary incontinence and urge urinary incontinence symptoms.
Interventions
DRUGDuloxetine hydrochloride
DRUGplacebo
Sponsors
Boehringer Ingelheim
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
FEMALE
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* female outpatient greater than or equal to 65 years of age * have symptoms of SUI or stress-predominant MUI for at least 3 consecutive months * have at least 7 incontinence episodes per week. For patients with MUI, at least 50% of the IEF must be due to stress. * is ambulatory and able to use a toilet independently and without difficulty
Exclusion criteria
* at Visit 1 have a positive urine culture or a history of four or more urinary tract infections (UTIs) in the preceding year * have had continence surgery or received bladder neck bulking agent therapy within 3 months prior to study entry * began pelvic floor muscle exercises (for example, Kegel or biofeedback) within 3 months prior to study entry or at any time during the study. * have neurologic lesions or conditions (e.g. multiple sclerosis, spinal cord lesions or Parkinson's disease) or local lesions (e.g. bladder stones present or tumors) that affect the lower urinary tract. * intake of monoamine oxidase inhibitors (MAOIs) within 14 days prior to randomisation or at any time during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess the efficacy of duloxetine for up to 12 weeks, compared to placebo, in community dwelling women > or = 65 years of age with symptoms of pure stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in mean time between voids | — |
| Percent change in the number of continence pads used per week | — |
| Change in the Incontinence Quality of Life total score and 3 sub-domain scores | — |
| Responder analysis based on the established within-treatment minimal clinically important difference established for the I-QOL | — |
| Responder analysis based on percent change in IEF | — |
| Compare the efficacy of duloxetine 40 mg twice daily with that of placebo in the treatment of the symptoms of SUI and stress-predominant MUI as measured by:Absolute change in IEF | — |
| Compare efficacy of duloxetine 40 mg twice daily with that of placebo as measured by the percent change in IEF using in the SUI and MUI subgroups | — |
| To assess the impact of treatment with duloxetine 40 mg twice daily and placebo on the development of suicidal ideation. | — |
| Assess the impact of treatment with duloxetine 40 mg twice daily and placebo in cognition. | — |
| Assess the impact of treatment with duloxetine 40 mg twice daily and placebo as measured by changes in BDI-II. | — |
| To compare the safety of duloxetine with placebo based on changes in vital signs, clinical lab values, occurrence and duration of adverse events and premature discontinuation of study due to adverse events. | — |
| Patient's rating of improvement using the PGI-I | — |
Countries
France, Germany, Netherlands, South Africa, Spain, Sweden, Switzerland
Outcome results
None listed